Advancing CAR T Cells for the Treatment of Solid Tumors ~ Multidisciplinary Approaches to Cancer Highlights- Enduring

This CME activity is based on the slides and lectures presented by the faculty at the “Multidisciplinary Approaches to Cancer Symposium,” on October 10–13, 2019 at the Waldorf Astoria, Las Vegas, Nevada.

Each year, the American Cancer Society estimates the number of new cancer cases and deaths that will occur in the United States. A total of 1,762,450 new cancer cases and 606,880 cancer deaths are projected to occur in the United States in 2019. Because they are so diverse in their individual biology, clinical course management of many of these cancers is increasingly difficult, constantly evolving and fraught with controversy. In this environment, it has become much more difficult and complicated for those involved in the care of cancer patients to remain current in best practice for each of the many tumor types that constitute “CANCER”. This year, our faculty  will profile and discuss the clinical and technical advances, promising clinical trials data, national guidelines and key controversies in the management of cancer. 

Target Audience

Internists, family practitioners, gynecologists, general surgeons, medical oncologists, radiation oncologists, surgical oncologists, hematologists,  gastroenterologists, urologists, dermatologists, supportive/palliative care specialists and all other allied health care professionals interested in the subject matter.

Learning Objectives

  • Examine what a T cell immunotherapy approach is, specifically what CAR T cell therapy refers to.
  • Identify some of the challenges that are being overcome to develop effective therapies for solid tumors.
Activity summary
Available credit: 
  • 0.75 AMA PRA Category 1 Credit™
    City of Hope is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
    City of Hope designates this Advancing CAR T Cells for the Treatment of Solid Tumors ~ Multidisciplinary Approaches to Cancer Highlights- Enduring for a maximum of 0.75 AMA PRA Category 1 Credit™ requirements. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • 0.75 Attendance
Activity opens: 
03/02/2020
Activity expires: 
03/02/2021

This activity has been planned and implemented in strict compliance with the accreditation requirements, standards, and policies of the ACCME. City of Hope takes responsibility for the content, quality and scientific integrity of this CME activity.

As an accredited CME provider City of Hope requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse that could create a conflict of interest. Any potential conflicts relative to the previous disclosure have been resolved.

Presenter: Dr. Saul Priceman has indicated  that he receives Grant/Research Support from PICI and Mustang; Consultant for Mustang and Apterna.

City of Hope further encourages faculty/ authors to identify investigational products or off-label uses of products regulated by the U.S. Food and Drug Administration, at first mention and where appropriate in the content.

Dr. Priceman will be discussing the off-label or investigational use of CAR T Cells.

The information and opinions presented in this activity do not constitute medical or legal advice. Health care providers must exercise their own professional judgment in their clinical practice, and when confronted with the issues discussed herein, should not substitute this curriculum for the advice of legal counsel or application of sound ethical principles.

ACCREDITATION STATEMENT: City of Hope is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION: City of Hope designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

The following credit type(s) are being offered for this course:

 •  AMA PRA Category 1™  0.75

The following may apply AMA PRA Category 1 Credit™ for license renewal:

Registered Nurses: Nurses may report up to 0.75 credit hours toward the continuing education requirements for license renewal by their state Board of Registered Nurses (BRN). AMA PRA Category 1 Credit™ may be noted on the license renewal application in lieu of a BRN provider number.

Physician Assistants: The National Commission on Certification of Physicians Assistants states that AMA PRA Category 1 Credit™ accredited courses are acceptable for CME requirements for recertification.
 

Available Credit

  • 0.75 AMA PRA Category 1 Credit™
    City of Hope is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
    City of Hope designates this Advancing CAR T Cells for the Treatment of Solid Tumors ~ Multidisciplinary Approaches to Cancer Highlights- Enduring for a maximum of 0.75 AMA PRA Category 1 Credit™ requirements. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • 0.75 Attendance
Please login or register to take this activity.

If you would like to take this Enduring course, please click on Take Course to register.

Required Hardware/software

Current version of Edge, Firefox, Safari, or Chrome.